Celgene Corporation (CELG) Reports Q3 EPS of $0.56
More News related to CELG
- Celgene Corporation to Present at the NASDAQ OMX 23rd Investor Program
- Celgene Corporation to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
- More Than 200 Abstracts Evaluating Celgene Products across a Range of Indications to Be Presented at the 51st American Society of Hematology Meeting
- Celgene Corporation to Present at Two Upcoming Investor Conferences
- Celgene Corporation to Present at the Oppenheimer & Co. Inc. 20th Annual Healthcare Conference
Celgene Corporation (NASDAQ: CELG) reports Q3 EPS of $0.56, cents better than the analyst estimate of $0.54. Revenue for the quarter was $692.2 million, which compares to the estimate of $671.89 million.
Related Categories
EarningsStocks Mentioned
-0.78Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
